Kefir Peptide Up-regulates BDNF to Alleviate Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression are often ineffective for a third of patients and conventional antidepressants have a high risk of prolonged metabolism, leading to potential suicidal tendencies due to their slow metabolism and long duration in the body, necessitating the development of more effective and safer alternatives.
Innovation Solution
A kefir peptide with an antidepressant activity, capable of up-regulating BDNF expression in hippocampal tissues and activating downstream targets, is isolated from a milk fermentation product and administered to improve or suppress depressive behaviors without adverse side effects, potentially through food, pharmaceutical, or nutriment compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antidepressants are administered to treat depression, then depressive behaviors are suppressed, but the drugs stay in the body for a longer period of time causing higher risk for suicidal tendencies
Solution Approach 1:
The patent extracts the active antidepressant component (kefir peptide) from the complex kefir fermented milk product. This isolation allows for targeted administration of the effective substance without the metabolic burden of other components, achieving depression treatment effectiveness while avoiding the prolonged metabolism issue of conventional drugs.
Solution Approach 2:
The patent changes the chemical parameter of the treatment agent from synthetic conventional antidepressants to a natural peptide with different metabolic properties. The kefir peptide exhibits rapid metabolism and elimination from the body, fundamentally altering the duration of action parameter to reduce suicidal risk while maintaining antidepressant effectiveness.
2Duration of action of stationary object
If conventional antidepressants are used for long-term treatment, then depressive behaviors are controlled, but adverse effects and side effects occur
Solution Approach 1:
The kefir peptide functions as a short-acting treatment agent that is rapidly metabolized and eliminated from the body. This short-living characteristic allows for repeated long-term administration without accumulation of harmful substances, enabling sustained depression control without the adverse effects associated with long-term conventional antidepressant use.
3Adaptability or versatility
If kefir fermented milk is used for various health benefits, then obesity, gastrointestinal diseases, and allergies are improved, but there is no confirmation of its capability to suppress depressive behaviors
Solution Approach 1:
The patent extracts and identifies the specific kefir peptide responsible for antidepressant activity within the complex kefir fermented milk matrix. This extraction resolves the information gap by isolating and characterizing the active component, confirming its antidepressant efficacy through targeted research while preserving the versatility of the source material for multiple health applications.
Data Source
AI summary
The invention discloses that a kefir peptide with an amino acid sequence of SEQ ID No: 2 or a fermentation product comprising the kefir peptide has an antidepressant activity, which means that by administering an effective amount of the kefir peptide or a composition comprising an effective amount of the kefir peptide to an individual with depressive behaviors is capable of effectively improving or alleviating the individual's depressive behaviors. Since the kefir peptide disclosed in the invention is not a chemical compound, the kefir peptide will not have side effects on the human body even taking it on a long-term basis.